• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

每周一次胰高血糖素样肽-1 受体激动剂阿必鲁肽与基础胰岛素联合治疗与餐时胰岛素联合基础胰岛素治疗 2 型糖尿病患者的 52 周结果。

Once weekly glucagon-like peptide-1 receptor agonist albiglutide vs. prandial insulin added to basal insulin in patients with type 2 diabetes mellitus: Results over 52 weeks.

机构信息

Li Ka Shing Knowledge Institute and Keenan Research Centre for Biomedical Science, St. Michael's Hospital, University of Toronto, 61 Queen St. East #6121, Toronto, Canada, M5C 2T2.

Hospital Moinhos De Vento, Rua. Ramiro Barcelos, 910, Floresta, Porto Alegre, RS, Brazil.

出版信息

J Diabetes Complications. 2017 Aug;31(8):1283-1285. doi: 10.1016/j.jdiacomp.2017.05.010. Epub 2017 May 25.

DOI:10.1016/j.jdiacomp.2017.05.010
PMID:28587789
Abstract

We have previously reported that once-weekly albiglutide was noninferior to thrice-daily lispro for glycemic lowering, with decreased weight and risk of hypoglycemia, in patients inadequately controlled on basal insulin over 26 weeks. Findings after 52 weeks reveal similar responses to albiglutide as an add-on to insulin glargine.

摘要

我们之前曾报道过,在 26 周的时间里,对于基础胰岛素控制不佳的患者,每周一次的阿必鲁肽与每日三次的赖脯胰岛素相比,在降低血糖方面不劣效,且体重减轻和低血糖风险降低。52 周后的研究结果显示,阿必鲁肽作为胰岛素甘精的附加疗法,具有相似的应答效果。

相似文献

1
Once weekly glucagon-like peptide-1 receptor agonist albiglutide vs. prandial insulin added to basal insulin in patients with type 2 diabetes mellitus: Results over 52 weeks.每周一次胰高血糖素样肽-1 受体激动剂阿必鲁肽与基础胰岛素联合治疗与餐时胰岛素联合基础胰岛素治疗 2 型糖尿病患者的 52 周结果。
J Diabetes Complications. 2017 Aug;31(8):1283-1285. doi: 10.1016/j.jdiacomp.2017.05.010. Epub 2017 May 25.
2
Impact of a Weekly Glucagon-Like Peptide 1 Receptor Agonist, Albiglutide, on Glycemic Control and on Reducing Prandial Insulin Use in Type 2 Diabetes Inadequately Controlled on Multiple Insulin Therapy: A Randomized Trial.每周一次胰高血糖素样肽-1 受体激动剂艾塞那肽对血糖控制和降低 2 型糖尿病患者经多次胰岛素治疗血糖控制不佳时餐时胰岛素用量的影响:一项随机试验。
Diabetes Care. 2020 Oct;43(10):2509-2518. doi: 10.2337/dc19-2316. Epub 2020 Jul 21.
3
Advancing basal insulin replacement in type 2 diabetes inadequately controlled with insulin glargine plus oral agents: a comparison of adding albiglutide, a weekly GLP-1 receptor agonist, versus thrice-daily prandial insulin lispro.在口服药物联合甘精胰岛素治疗未能充分控制的 2 型糖尿病患者中,强化基础胰岛素替代治疗:比较每日一次给予阿必鲁肽(一种每周一次的 GLP-1 受体激动剂)与每日三次给予赖脯胰岛素的疗效。
Diabetes Care. 2014 Aug;37(8):2317-25. doi: 10.2337/dc14-0001. Epub 2014 Jun 4.
4
Placebo-controlled, randomized trial of the addition of once-weekly glucagon-like peptide-1 receptor agonist dulaglutide to titrated daily insulin glargine in patients with type 2 diabetes (AWARD-9).安慰剂对照、随机试验,观察每周一次胰高血糖素样肽-1 受体激动剂度拉鲁肽添加至滴定剂量每日胰岛素甘精的疗效,该研究纳入了 2 型糖尿病患者(AWARD-9)。
Diabetes Obes Metab. 2017 Jul;19(7):1024-1031. doi: 10.1111/dom.12937. Epub 2017 Apr 10.
5
Effect of exenatide QW or placebo, both added to titrated insulin glargine, in uncontrolled type 2 diabetes: The DURATION-7 randomized study.度易达®(艾塞那肽周制剂)或安慰剂联合滴定胰岛素甘精治疗未控制 2 型糖尿病的疗效:DURATION-7 随机研究。
Diabetes Obes Metab. 2018 Jul;20(7):1602-1614. doi: 10.1111/dom.13266. Epub 2018 Mar 25.
6
Glucagon-like peptide 1 receptor agonist or bolus insulin with optimized basal insulin in type 2 diabetes.胰高血糖素样肽 1 受体激动剂或速效胰岛素联合优化基础胰岛素治疗 2 型糖尿病。
Diabetes Care. 2014 Oct;37(10):2763-73. doi: 10.2337/dc14-0876. Epub 2014 Jul 10.
7
Tirzepatide vs Insulin Lispro Added to Basal Insulin in Type 2 Diabetes: The SURPASS-6 Randomized Clinical Trial.替尔泊肽对比赖脯胰岛素添加至基础胰岛素治疗 2 型糖尿病:SURPASS-6 随机临床试验。
JAMA. 2023 Nov 7;330(17):1631-1640. doi: 10.1001/jama.2023.20294.
8
Efficacy and safety of MYL-1501D vs insulin glargine in patients with type 1 diabetes after 52 weeks: Results of the INSTRIDE 1 phase III study.在 52 周后,MYL-1501D 对比甘精胰岛素在 1 型糖尿病患者中的疗效和安全性:INSTRIDE 1 期 III 期研究结果。
Diabetes Obes Metab. 2018 Aug;20(8):1944-1950. doi: 10.1111/dom.13322. Epub 2018 May 7.
9
Cost-effectiveness of exenatide twice daily vs insulin glargine as add-on therapy to oral antidiabetic agents in patients with type 2 diabetes in China.在中国 2 型糖尿病患者中,每日两次艾塞那肽与甘精胰岛素作为口服降糖药的附加疗法的成本效益比较。
Diabetes Obes Metab. 2017 Dec;19(12):1688-1697. doi: 10.1111/dom.12991. Epub 2017 Jul 20.
10
Efficacy and safety of once-weekly glucagon-like peptide 1 receptor agonist albiglutide (HARMONY 1 trial): 52-week primary endpoint results from a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes mellitus not controlled on pioglitazone, with or without metformin.每周一次胰高血糖素样肽-1受体激动剂阿必鲁肽的疗效与安全性(HARMONY 1试验):一项针对使用吡格列酮(无论是否联用二甲双胍)血糖控制不佳的2型糖尿病患者进行的随机、双盲、安慰剂对照试验的52周主要终点结果
Diabetes Obes Metab. 2014 Dec;16(12):1257-64. doi: 10.1111/dom.12382. Epub 2014 Oct 6.

引用本文的文献

1
Efficacy and Safety of Tirzepatide Compared with GLP-1 RAs in Patients with Type 2 Diabetes Treated with Basal Insulin: A Network Meta-analysis.在接受基础胰岛素治疗的2型糖尿病患者中,替尔泊肽与胰高血糖素样肽-1受体激动剂相比的疗效和安全性:一项网状Meta分析
Diabetes Ther. 2025 Jun;16(6):1279-1311. doi: 10.1007/s13300-025-01728-5. Epub 2025 Apr 11.
2
Efficacy and safety of albiglutide, a once-weekly glucagon-like peptide-1 receptor agonist, in patients with type 2 diabetes: A systematic review and meta-analysis.每周一次胰高血糖素样肽-1 受体激动剂阿必鲁肽治疗 2 型糖尿病患者的疗效和安全性:系统评价和荟萃分析。
Medicine (Baltimore). 2024 Jun 21;103(25):e38568. doi: 10.1097/MD.0000000000038568.
3
American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update.
美国临床内分泌学会临床实践指南:制定糖尿病综合护理计划-2022 更新版。
Endocr Pract. 2022 Oct;28(10):923-1049. doi: 10.1016/j.eprac.2022.08.002. Epub 2022 Aug 11.
4
GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art.GLP-1 受体激动剂在 2 型糖尿病治疗中的应用——最新进展。
Mol Metab. 2021 Apr;46:101102. doi: 10.1016/j.molmet.2020.101102. Epub 2020 Oct 14.
5
GLP-1 receptor agonists and risk of cancer in type 2 diabetes: an updated meta-analysis of randomized controlled trials.GLP-1 受体激动剂与 2 型糖尿病患者癌症风险:一项随机对照试验的更新荟萃分析。
Endocrine. 2019 Nov;66(2):157-165. doi: 10.1007/s12020-019-02055-z. Epub 2019 Aug 16.
6
Risk of Malignant Neoplasia with Glucagon-Like Peptide-1 Receptor Agonist Treatment in Patients with Type 2 Diabetes: A Meta-Analysis.GLP-1RA 治疗 2 型糖尿病患者的恶性肿瘤风险:一项荟萃分析。
J Diabetes Res. 2019 Jul 16;2019:1534365. doi: 10.1155/2019/1534365. eCollection 2019.
7
A Review of the Safety and Adverse Event Profile of the Fixed-Ratio Combination of Insulin Glargine and Lixisenatide.甘精胰岛素与利司那肽固定比例复方制剂的安全性及不良事件概述
Diabetes Ther. 2019 Feb;10(1):21-33. doi: 10.1007/s13300-018-0547-5. Epub 2018 Dec 11.